Overview

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs), withdrawal of subjects due to AEs, reporting of Serious AEs (SAEs).

Phase:

Phase 3

Details

Lead Sponsor:

UCB BIOSCIENCES GmbH

Collaborator:

Eden Sarl

Treatments:

Carbamazepine
Lacosamide